Retrospective analysis reveals that rituximab maintenance improves overall survival and event-free survival in mantle cell lymphoma patients.
Key Points
Overall survival for patients with mantle cell lymphoma was found to be 43 months, indicating a critical survival outcome in this cohort.
Kaplan-Meier analysis revealed estimated 3-year overall survival and event-free survival rates of 60% and 35%, respectively, showing notable treatment effectiveness.
Retrospective analysis of 98 patients was conducted to evaluate clinicopathologic characteristics at a tertiary care center in North India.
Rituximab maintenance significantly improved survival outcomes, suggesting that further studies should explore this treatment's benefits in larger cohorts.